This work not only identifies SLAMF7 as a central player in IBD pathogenesis but also provides a foundational framework for developing macrophage-centric therapies to improve long-term outcomes in individuals with refractory or relapsing disease. Here, SLAMF7 is linked to inflammatory bowel disease.